Ray Dalio Alnylam Pharmaceuticals, Inc. Transaction History
Bridgewater Associates, LP
- $17.3 Billion
- Q3 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 2,002 shares of ALNY stock, worth $485,485. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,002Holding current value
$485,485% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding ALNY
# of Institutions
643Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.06 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.32 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.27 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.2 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...